肺癌与头颈癌免疫治疗格局更新
综述概述了肺癌与头颈鳞状细胞癌(HNSCC)的免疫治疗现状与未来方向。程序性死亡配体1/程序性死亡1(PD-L1/PD-1)检查点抑制剂已获批用于约18种组织学类型癌症,其中肺癌和HNSCC是免疫治疗发展的引领者。阿替利珠单抗、度伐利尤单抗、纳武利尤单抗和帕博利珠单抗已用于不同分期肺癌的标准治疗,纳武利尤单抗和帕博利珠单抗获美国监管批准用于晚期转移性HNSCC。目前多数免疫治疗获批用于转移性患者,早期疾病研究正在进行中。
要点
- PD-L1/PD-1检查点抑制剂已获批用于约18种组织学类型癌症。
- 四种PD-1/PD-L1抑制剂已用于不同分期肺癌标准治疗。
- 纳武利尤单抗和帕博利珠单抗获批用于晚期转移性HNSCC。
核心结论
- 免疫治疗已显著改变肺癌和HNSCC的治疗格局,但多数获批仍限于转移性设置。
研究设计与样本
- 本文为综述,旨在概述肺癌与HNSCC的当前免疫格局和未来方向。
主要发现
- 目前有6种美国食品药品监督管理局(FDA)批准的检查点抑制剂用于约18种不同组织学类型的癌症。
- 阿替利珠单抗、度伐利尤单抗、纳武利尤单抗和帕博利珠单抗均用于不同分期肺癌的标准治疗。
- 纳武利尤单抗和帕博利珠单抗获美国监管批准用于晚期转移性HNSCC。
- 肺癌是全球最常见且最致命的癌症,HNSCC是第六常见癌症。
临床怎么用
- 肺癌和HNSCC的免疫治疗应依据获批适应症和分期选择PD-1/PD-L1抑制剂。
- 目前多数免疫治疗批准用于转移性患者,早期疾病使用需等待研究结果。
局限性
- 本文为综述,未报告原始研究数据或定量合并结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Immunotherapy has dramatically changed the treatment landscape for patients with cancer. Programmed death-ligand 1/programmed death-1 checkpoint inhibitors have been in the forefront of this clinical revolution. Currently, there are 6 US Food and Drug Administration-approved checkpoint inhibitors for approximately 18 different histologic types of cancer. Lung cancer and head and neck squamous cell carcinoma (HNSCC) are 2 diseases that have led the way in the development of immunotherapy. Atezolizumab, durvalumab, nivolumab, and pembrolizumab are all currently used as part of standard-of-care treatment for different stages of lung cancer. Similarly, nivolumab and pembrolizumab have US regulatory approval as treatment for advanced metastatic HNSCC. This is significant because lung cancer represents the most common and most fatal cancer globally, and HNSCC is the sixth most common. Currently, most of the approvals for the use of immunotherapy agents are for patients diagnosed in the metastatic setting. However, research is ongoing to evaluate these drugs in earlier stage disease. There is plausible biological rationale to expect that pharmacologic activation of the immune system will be effective for early-stage and smaller tumors. In addition, selecting patients who are more likely to respond to immunotherapy and understanding why resistance develops are crucial areas of ongoing research. The objective of this review was to provide an overview of the current immune landscape and future directions in lung cancer and HNSCC.
引用
- Carlisle JW, Steuer CE, Owonikoko TK, et al. An update on the immune landscape in lung and head and neck cancers. CA Cancer J Clin. 2020. PMID: 32841388. doi:10.3322/caac.21630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。